In this study we demonstrate that cancer-associated fibroblasts (CAFs) in high-grade serous ovarian cancer are heterogeneous, that CAF state drives cancer aggressiveness and patient outcomes, and that TCF21 is a master regulator of CAF state.
Introduction
High grade serous ovarian cancer (HGSOC) is the most common histological subtype of ovarian cancer and is typically diagnosed at an advanced stage (1) . Optimal surgical debulking and platinum/taxane-based chemotherapy significantly increase the survival of HGSOC patients, but the vast majority relapse within 5 years of diagnosis and die of their disease (1) . Due to early dissemination and implantation of cancer cells within the peritoneal cavity, HGSOC patients typically present at late stage with widespread abdominal disease, and nearly invariably develop chemotherapy resistance. In spite of recent advances with targeted therapies such as PARP inhibitors (2) , bevacizumab (3) , and immune checkpoint blockade (4) , these approaches do not currently benefit all patients and mortality rates remain high. The development of more effective treatments for HGSOC patients thus remains a necessary and important goal.
Cancer-associated fibroblasts (CAFs) are a key component of the tumor microenvironment and have several differences relative to their normal counterparts, including increased proliferation, extracellular matrix production, and expression of cytokines and growth factors (5) .
In many cancers, including HGSOC, CAFs have important effects on tumor behavior, including defining the rate and extent of cancer progression through inhibition of cancer cell apoptosis, induction of cancer cell proliferation, promotion of cancer cell migration and invasion and mediation of chemotherapy resistance (6) (7) (8) (9) (10) . More recently CAFs have also been shown to mediate immune-suppression (11) (12) (13) , adding another layer of complexity to their pro-tumorigenic role. A variety of markers have been used to identify CAFs, including α-smooth muscle actin (SMA), platelet-derived growth factor receptors (PDGFRs) and fibroblast activation protein (FAP), and most studies have focused on CAFs that express these markers. More recent studies have shown that CAFs are heterogeneous, and CAF subtypes with distinct phenotypes have begun to be identified in various malignancies (14) (15) (16) (17) (18) . However, while CAFs with distinct phenotypes have been identified in several cancers, the functional characterization of these cells and their effects on tumor progression and patient outcomes have not yet been revealed. Furthermore, molecular mechanisms driving epigenetic differences between CAF subtypes remain uncharacterized.
Here we describe the identification of CD49e as a novel cell surface marker for fibroblasts within HGSOC primary tumor tissues, and discover two distinct CAF states that exist within the CD49e+ fibroblast compartment and can be distinguished based on fibroblast-activation protein (FAP) expression. We demonstrate that FAP-high (FH) and FAP-low (FL) CAFs co-exist at varying ratios in individual tumors and, importantly, CAF status drives patient outcomes. Purified FH and FL CAFs have distinct transcriptional signatures that are prognostic in the TCGA cohort, and in vitro and in vivo functional assays reveal differences in their ability to promote cancer cell proliferation, invasion and chemo-resistance. Finally, we show that transcription factor TCF21 is a master regulator of the CAF state. Our extensive molecular and functional characterization of CAFs and analysis of CAF-derived gene signatures in relation to patient outcomes provides novel insights into the significant role of this cell population in HGSOC disease progression, and the potential of manipulating the CAF state as a therapeutic strategy.
Results

Isolation and transcriptional profiling of CAFs from primary HGSOC tumor samples
All tumor samples used in this study are listed in Table S1a . Purification of viable CAFs directly from primary tumors using fluorescence activated cell sorting (FACS) requires a robust cell surface marker. PDGFR-β and FAP are commonly used CAF markers but we found these to be either dimly or inconsistently expressed in single cell suspensions from primary HGSOC samples, in line with other studies showing that expression of established CAF markers is heterogeneous and non-overlapping (18, 19) . We therefore used high-throughput flow cytometry with a panel of 363 antibodies targeting cell surface proteins (20) to analyze cultured CAF lines derived from four HGSOC patients and single cell suspensions from five primary HGSOC samples. The latter were co-stained for CD45 and CD31 to allow exclusion of contaminating immune and endothelial cells, respectively. From this screen we identified several proteins that were uniformly highly expressed on the cultured CAFs, but only stained a minority of the CD45-/CD31-cells from primary HGSOC samples, which would be expected to contain a mixture of cancer cells and CAFs (Figure S1 ). The greatest difference was seen for CD49e (ITGA5), which was selected for follow-up. Immunofluorescence studies of HGSOC sections confirmed that CD49e antibody selectively stained the tumor stromal compartment, while pan-CK antibody, as expected, stained tumor cells ( Figure 1A) . Co-staining with an anti-EpCAM antibody (an epithelial cell marker) enabled clear distinction and isolation of CAFs from HGSOC samples as the CD45-CD31-EpCAM-CD49e+ fraction, which varied in frequency between patients ( Figure   1B) . The identity of isolated CD45-CD31-EpCAM+CD49e-(referred to as EpCAM+) and CD45-CD31-EpCAM-CD49e+ (referred to as CD49e+) fractions as cancer cells and CAFs, respectively, was further validated by generating cytospins of the purified populations and staining them for pan-CK, Vimentin and p53. The CD49e+ fraction was positive for Vimentin and negative for pan-CK, as would be expected for a fibroblast population (Figure 1C ). In addition, in patients for whom the EpCAM+ fraction showed strong nuclear P53 staining, indicative of mutant P53 (21) , the CD49e+ fraction was negative for P53 staining, demonstrating that CD49e+ cells do not bear the cancer-associated mutation and ruling out the possibility that they are cancer cells that underwent an epithelial-to-mesenchymal transition (EMT; Figure 1D ).
To interrogate the transcriptional profiles of cells isolated directly from primary tumor specimens, FACS was used to isolate the CD49e+ fraction and the EpCAM+ fraction from 12 primary HGSOC samples ( Figure S2A) . The latter was further fractionated into EpCAM+CD133+ and EpCAM+CD133-fractions, as we had previously shown that CD133 was a marker of tumorinitiating cells in the majority of primary HGSOC solid tumors (22) . RNA was extracted and analyzed using Illumina HT-12v4 microarrays. Upon unsupervised analysis, CD133+ and CD133subsets had very similar transcriptional profiles and clustered together, whereas the CD49e+ population formed a distinct cluster ( Figure 1E) . The CD49e+ fraction expressed known CAFassociated genes, including ACTA2, FAP, VIM, POSTN, SPARC, and multiple collagen genes, among others (Table S2A) . Gene set enrichment analysis (GSEA) was carried out on differentially expressed genes between CD49e+ cells and EpCAM+ cells using the MsigDB Reactome database. EpCAM+ cells were enriched for genes related to cell proliferation, metabolism and epithelial identity (e.g., tight junction interactions, cell-cell junction organization), whereas the CD49e+ subset was enriched for gene sets involved in extracellular matrix organization, myogenesis and known mesenchymal signaling pathways, such as PDGF, FGF and RHO GTPase signaling (23, 24) . These results further confirm the identity of our purified CD49e+ population as fibroblasts ( Figure 1F , Table S2B ).
The CD49e+ fraction separates into 2 clusters
Unsupervised hierarchical clustering of the gene expression data indicated that the CD49e+ CAF population segregated into two sub-clusters ( Figure 1E, Figure S2B ), suggesting that CAFs derived from HGSOC patients are heterogeneous. One cluster expressed classical CAF-related genes, such as FAP, TGFβ, COL11A1, SULF1 and inflammatory cytokines (e.g., IL-6, CXCL12), among others, whereas the other exhibited a distinct gene expression profile that included low expression of the classical CAF marker FAP (Figure 2A , Table S3A ). We therefore refer to these two groups of patients as "FAP-high" (FH) and "FAP-low" (FL). Several of the FH (FAP, COL11A1, SULF1)-and FL (DLK1, TCF21, COLEC11)-specific genes were validated by reversetranscription and quantitative polymerase chain reaction (qRT-PCR) on RNA isolated from the CD49e+ fraction of six patients included in the microarray analysis, three from the FH group and three from the FL group (Figure 2B) . To test whether the two CAF subtypes were a general feature of ovarian cancer stroma, we analyzed the gene expression data set generated by Leung and colleagues (25) who used laser capture microdissection to isolate stromal and epithelial components from 31 HGSOC specimens and 8 normal ovary specimens. We interrogated the expression of the top 500 differentially expressed genes between our FH and FL patients in the stromal samples from this cohort and again found two major clusters (Figure 2A) . This result verified the ability of our FH vs FL gene list to segregate HGSOC patients into two subtypes based on expression of these genes in their stroma. Importantly, the transcriptional profile of normal ovarian stroma was distinct from the FL cancer stroma, indicating that FL CAFs represent a distinct phenotype of stromal cells within HGSOC, and not normal fibroblasts (Figure S2C-D and Table   S3B ).
FH and FL fibroblasts co-exist in the majority of patients.
To further interrogate the FH and FL status of patients classified into these groups by gene expression analysis, we performed immunofluorescence (IF) staining for FAP, TCF21 (a highlyexpressed FL gene) and pan-CK on serial sections from five tumors categorized as FH (n=3) or FL (n=2) by microarray. The slides were scanned to generate high resolution digital images of the entire section, and the FAP-positive or TCF21-positive stained areas within the Pan-CK negative, stromal regions were quantified using HALO image analysis software (Figure 2C and Figure   S3 ). This analysis showed that FH patients indeed had more FAP-expressing cells in their tumor stroma than FL patients, whereas TCF21-expressing cells were more abundant in FL patients.
However, we also noticed that within tumor samples, FAP-positive and TCF21-positive cells could both be observed, and regions with predominantly one type of CAF or the other could be identified ( Figure 2D) . Nevertheless, quantification by HALO indicated an anti-correlation between FAP and TCF21 expression ( Figure 2E) . Thus FH and FL CAFs are two distinct subtypes that co-exist within HGSOC tumors at varying ratios.
To more accurately quantify FH and FL CAFs within patient specimens, we performed flow cytometry on 66 HGSOC samples, with the addition of a FAP antibody to the previous combination of CD45, CD31, EpCAM and CD49e, allowing us to quantify FAP expression within the CD49e+ fraction. The FH subset ranged from 0.6% to 98% within the CD49e+ population ( Figure 2F) . Of the 5 patient samples that were also stained by IF, the flow cytometry and immunofluorescence assays showed a strong positive correlation in the proportion of cells expressing FAP (r=0.969).
Transcriptional profiling of purified FH and FL cells
Our initial gene expression analysis was performed on the bulk CD49e+ fraction, which contained mixtures of FH and FL CAFs at varying ratios, suggesting that the observed clustering of patients into FH and FL groups reflected the predominant population, but these populations were not pure. We therefore carried out RNA-Seq analysis on FH and FL CAFs purified by FACS.
For some of these samples, the CD49e+ fraction was predominantly FH or FL, making isolation of both fractions in sufficient numbers difficult; however, for three patients (72143, 70535 and 71423), we successfully generated high-quality RNA-Seq data on both fractions. Principal component analysis of the five FH populations and four FL populations showed that regardless of whether the samples were derived from a FH patient or a FL patient, the samples clustered based on FAP status ( Figure 3A) . Gene set enrichment analysis (GSEA) comparing the genes differentially expressed in isolated FH and FL cells showed a very high concordance with the previously obtained microarray-derived gene lists ( Figure 3B ). In addition, FAP, COL11A1 and SULF1 were highly expressed in the FH subset, and TCF21, COLEC11 and DLK1 were highly expressed in the FL subset ( Figure 3C) . These results confirm that HGSOC samples contain mixtures of FH and FL CAFs at varying ratios, and that the clustering of patients based on bulk fibroblast profiling was driven by whichever population was dominant in those tumors. There were 800 differentially expressed genes between FH and FL CAFs at a false discovery rate (FDR) value of ≤0.05 (Table S4A ). GSEA of the differentially expressed genes between FH and FL cells ( Figure 3D ) showed that FH cells express genes involved in ECM reorganization, cell migration and chemotaxis, immune regulation (including neutrophil activation, regulation of defense response and antigen processing), and regulation of angiogenesis, and thus resemble the classical phenotype that is commonly associated with CAFs in the literature (11, 23, 26) . By contrast, the most dominant gene sets expressed in FL CAFs include glucose/insulin homeostasis, cardiac muscle contraction and ion transport, translation and protein localization, and lipid metabolism. FL CAFs thus represent a previously unrecognized CAF subtype with a distinct gene expression profile from FH CAFs.
FH and FL patients can be identified in The Cancer Genome Atlas (TCGA) HGSOC dataset and have distinct clinical outcomes.
Gene expression profiling of 489 HGSOC samples by TCGA previously led to identification of four molecular subtypes: mesenchymal, proliferative, differentiated, immunoreactive (27) .
Refined signatures for these subtypes were subsequently generated, and the mesenchymal subtype was found to be associated with worse outcome (28) . We generated a gene signature based on FH and FL CAF genes by filtering for genes that were both differentially expressed in purified FH vs FL cells, and differentially expressed in CAFs compared to EpCAM+ cells in our original microarray data set. This analysis resulted in a list of 165 FH-specific genes and 78 FL-specific genes ( Figure S4A , Table S5 ). We then interrogated this signature against TCGA RNA-Seq data (n = 374 patients) and found that FH and FL transcripts were detectable in a large number of patients, with distinct FH and FL clusters present ( Figure 4A ). A scoring system was established to classify patients ( Figure S4B ). When a patient expressed 75% of the FH genes at a level higher than the population mean, the patient was classified FH (shown in black in Figure 4A ). A second, less stringent threshold classified patients as FH if they expressed 50% of the FH genes above the mean (shown in grey in Figure 4A ). The same rule was applied to classify the FL patients (shown in red and pink, respectively in Figure 4A ). The majority of the FH patients overlapped with the TCGA mesenchymal subtype, whereas the FL patients were distributed amongst the mesenchymal, proliferative and differentiated subtypes ( Figure 4A , Figure S4C ). GSEA shows that the FH genes were highly enriched in the mesenchymal signature (28) whereas the FL genes were not ( Figure   4B ), suggesting that that the mesenchymal subtype is largely driven by the presence of FH fibroblasts.
Using the ABSOLUTE algorithm, which uses somatic copy number data to estimate the cellularity of tumor samples (29) , it was shown previously that the mesenchymal subtype in the TCGA HGSOC study had the lowest tumor purity (30) . Using the same algorithm, FH and FL TCGA patients both had lower tumor purities than the remaining "other" patients that did not fall into either category ( Figure 4C and Figure S4D ). Histopathology data for the TCGA samples also indicates that tumor samples in the "other" category had a lower stromal content than both the FH and FL categories ( Figure S4E ). Taken together, these findings suggest that the unclassified samples could not be classified as FH or FL due to low stromal content within the tumor specimen analyzed.
ESTIMATE is another algorithm designed to estimate the quantity of infiltrating fibroblasts and immune cells using gene expression data on tumor tissues (31) . While the ESTIMATE algorithm generated a high "stromal" score for the FH samples, it failed to identify higher stromal content in tumor samples falling into the FL category ( Figure 4C and Figure S4D ).
Deeper analysis of this discrepancy showed that the list of 141 genes used to define "stroma" in the ESTIMATE algorithm is enriched for FH genes (21-gene overlap), but not for FL genes (2gene overlap). As a result, patients with a high fraction of FL CAFs were not identified as having higher stromal content using this algorithm.
To determine if the CAF subtype has an impact on survival, we performed a Kaplan-Meier analysis of the TCGA patients that were classified as FH or FL (using the more stringent cut-off of 75%). FH patients had significantly shorter progression-free and overall survival than FL patients; the median overall survival of FL patients was 2 years longer than that of FH patients ( Figure 4D ). To validate this finding, we compared the %FAP+ CAFs from patients that were analyzed by flow cytometry in Figure 2F to progression-free survival for 46 of the patients for which these data were available. We defined FH patients as those with a %FAP+ CAFs above the median, and FL patients as those with a %FAP+ CAFs below the median. We found that FH patients had a significantly worse progression-free survival compared to FL patients ( Figure 4E) .
FL cells require different culture conditions than FH cells
Most studies of CAFs utilize cultures established by plating tumor cell suspensions onto tissue culture plastic in the presence of 10% fetal bovine serum (FBS). In these conditions, CAFs rapidly adhere and proliferate, allowing for their selection and outgrowth. Our identification of CD49e as a CAF marker was facilitated by analysis of such patient-derived cultured CAF lines.
Analysis of several of our cultured CAF lines indicated that they are FH by flow cytometry and express FH but not FL genes (data not shown). When we placed FH and FL cells purified by FACS directly from patient samples into standard 10% FBS conditions, we found that FH cells had a significantly higher growth rate than FL cells, and that FL cells in these conditions did not reach confluence and could not be successfully passaged (Figure 5A) ; thus when bulk cells are placed in culture to derive CAF lines FH cells will outcompete FL cells over time due to their growth advantage. We therefore sought alternative culture conditions for FL cells; based on the expression of some genes related to adipogenesis in our FL population (e.g. DLK1, PPARG), we tested commercially available pre-adipocyte media and found that this media supported the expansion of FL cells over multiple passages (Figure 5B) . qRT-PCR analysis of FH and FL genes indicated that FL cells continued to express FL genes (TCF21 and DLK1) at very high levels for up to 8 passages. However, we did see a decrease in these genes with increasing passage number, suggesting that even in pre-adipocyte media FL cells drift towards a FH phenotype with increasing time in culture ( Figure 5C ). We also saw an increase in FAP and SULF1 gene expression with passage in some cases (Figure 5C ). Thus to carry out the functional assays described below it was necessary to repeatedly isolate FL cells from patient samples and use them at passage 5 or less.
FH cells promote more gel contraction, cancer cell invasion and chemotherapy resistance than FL cells
A hallmark of CAFs is their ability to contract collagen gels (32) . Notably, two early passage FH CAF lines (851FH and 68425FH) showed a greater ability to contract collagen gels than two early passage FL CAF lines (507FL and 598FL; Figure 5D ). Another property commonly attributed to CAFs is the ability to promote cancer cell invasion (10, 33, 34) . To compare the ability of FH and FL CAFs to promote invasion, spheroids were established with GFP-expressing HGSOC cell lines OVCAR8, ES2 and OV90, either alone or together with FH CAFs or FL CAFs at a ratio of 5:1 (CAFs:cancer cells). The spheroids were embedded in Matrigel and imaged by fluorescence microscopy after a period of incubation at 37°C that was optimized for individual cell lines and different batches of Matrigel (Figure S5A) . For OVCAR8 and OV90 invasion was quantified by measuring the circularity of at least 5 spheroids per condition; a decrease in circularity is indicative of cells invading into the Matrigel, generating branches radiating away from the spheroids and thus causing spheroids to deviate from a circular shape. The invasion pattern of ES2 cells was distinct and consisted of individual cells migrating outwards into the Matrigel, rather than formation of branches. Invasion was therefore quantified by counting the number of cells outside of the sphere, rather than measuring circularity. Upon testing of FH and FL CAFs from multiple patients, FH CAFs had an overall significantly greater ability to promote the invasion of OVCAR8, ES2 and OV90 cells compared to FL CAFs. Notably, in cases where it was possible to assess patient-matched FH and FL CAFs (Patient 438 on all 3 cell lines; patient 598 on ES2 cells) there was a statistically significant difference, with FH CAFs inducing more invasion than FL CAFs (Figure 5E ).
The standard of care for patients with HGSOC includes treatment with platinum-based chemotherapy, and chemo-resistance is a major factor leading to poor outcome in this disease. We determined the IC50s for carboplatin in OVCAR8, ES2 and OV90 cells growing under adherent conditions on plastic and showed that they ranged from 6 to 24 µM at 5 days after treatment ( Figure S6A ). Based on this information, subsequent experiments were performed using 10 µM carboplatin. To determine if FH and/or FL CAFs could influence cancer cell responses to chemotherapy, GFP-labelled OVCAR8, ES2 or OV90 cells were seeded onto feeder layers of FH CAFs or FL CAFs in flat-bottom 96 well plates. The next day 10 µM carboplatin was added and cells were cultured for an additional 10 days. GFP+ cancer cells were quantified daily using an Incucyte Zoom live cell imaging system. Both OVCAR8 and ES2 cells were rendered more resistant to carboplatin treatment in the presence of FH CAFs compared to FL CAFs, as indicated by more robust growth and a larger number of cells remaining at the end of the 10-day treatment period in FH co-cultures ( Figure 5F ). This included two pairs of patient-matched FH and FL CAFs (598FH and FL; 438FH and FL) that showed distinct outcomes. OV90 cells did not display any differences. Notably, for the two separate batches of experiments performed ( Figure 5F ) 851FH CAFs were used in both, and displayed very reproducible growth curves in all three cell lines.
FH CAFs promote in vivo tumor growth and metastasis to lymph nodes.
To ask if FH and FL CAFs have distinct influences over cancer cell behavior in vivo, we generated spheroids as above using luciferase-tagged OVCAR8 cells and implanted single spheroids into the mammary fat pads of non-obese diabetic/severe combined immunodeficient/IL2R- double-knockout (NSG) mice ( Figure S5B) . We implanted spheroids into the mammary fat pad due to earlier work by our group showing more efficient HGSOC tumor growth at this site (22) . Tumor growth was monitored by serial imaging of luciferase activity ( Figure 6A ). Of 10 mice implanted in each group take rates were 6/10, 5/10, 6/10 and 9/10 for the no CAF control, 363FL CAFs, 374FL CAFs and 851FH CAFs, respectively, suggesting a possible enhancement of take rate in spheroids containing FH CAFs, although differences did not reach statistical significance. Tumors that contained FH CAFs (851FH) grew more rapidly compared to tumors containing FL CAFs (363FL or 374FL; Figure 6B ). Furthermore, 4 of 10 mice in the FH group had axillary lymph node or abdominal metastases compared to 0 of 5 mice and 1 of 6 mice in the two FL groups and 1 of 6 mice in the no CAF control group (Figure 6C) . Importantly, this held true when the mice injected with FL CAF-containing spheroids were maintained for an additional 3 weeks, allowing the size of their tumors to reach a size exceeding the FH tumors at week 8, indicating that the difference in metastasis was not simply a function of larger tumor size in the FH group.
Overexpression of TCF21 in FH CAFs inhibits their pro-tumorigenic functions.
TCF21 is the most highly expressed transcription factor in FL CAFs and is essential for the formation of cardiac fibroblasts during embryonic development (35) . TCF21 has differentiation inhibiting function in skeletal muscle and smooth muscle cells (36) (37) (38) and is also highly expressed in white adipose tissues (39) . Because lipid metabolism, ventricular development and cardiac related pathways were enriched in FL CAFs (Figure 3D) , we hypothesized that TCF21 might be a master regulator of FL CAF identity. To test this possibility, 851FH CAFs were transduced with lentiviral vectors expressing either TCF21 and GFP (851FH-TCF21) or GFP alone (851FH-GFP) and GFP+ cells were FACS-purified and briefly expanded. TCF21 expression was validated by Western blot, and qRT-PCR demonstrated up-regulation of TCF21 and two additional FL-specific transcripts (DLK and TGFBR3), as well as down-regulation of four FL-specific genes (FAP, SULF1, MMP1 and MFAP5; Figure 7A ). We then compared the functional properties of 851FH-TCF21 and 851FH-GFP cells. The ability of 851FH-TCF21 CAFs to contract collagen gels was decreased in comparison to 851FH-GFP cells (Figure 7B) . The spheroid invasion assay was carried out using mCherry labelled OVCAR8 and OV90 cells (because the 851FH-TCF21 and 851FH-GFP CAFs were GFP+), allowing imaging of both cancer and CAF cells in this assay. The invasion of both cell types was significantly reduced upon overexpression of TCF21 in 851FH CAFs (Figure 7C) . We next carried out co-cultures of OVCAR8, OV90 and ES2 cells with 851FH-TCF21 or 851FH-GFP CAFs in the presence of 10 µM carboplatin. OVCAR8 and ES2 cells grew more robustly in co-cultures with 851FH-GFP CAFs than in co-cultures with 851FH-TCF21 CAFs, suggesting that TCF21 expression reduced the ability of 851FH CAFs to promote the survival of cancer cells in the presence of carboplatin (Figure 7D) . Once again, no effect was seen with OV90 cells. Finally, heterospheroids composed of OVCAR8 cancer cells and 851FH-TCF21 or 851FH-GFP fibroblasts were implanted in the mammary fat pad and growth was monitored by serial imaging of luciferase activity (Figure 7E ). 15 of 15 mice implanted with 851FH-GFP-containing spheres grew tumors, whereas only 10 of 15 mice implanted with 851FH-TCF21-containing spheres grew tumors (p=0.042, Fisher's exact test). In addition, overexpression of TCF21 in 851FH CAFs led to a significant growth delay compared to the 851FH-GFP control ( Figure 7F ).
Discussion
In this study we demonstrate that CAFs in HGSOC are heterogeneous, that different subtypes have distinct influences on cancer aggressiveness and patient outcomes, and that TCF21 is a master regulator of CAF state. The identification of distinct CAF subtypes in HGSOC was facilitated by the identification of CD49e as a novel pan-fibroblast marker and the resulting ability to profile CAFs isolated directly from primary tumor specimens. We showed that patients with predominantly FH CAFs in their stroma have shorter disease-free and/or overall survival.
Functional assays demonstrated that FH CAFs promote cancer cell invasion, resistance to carboplatin, and proliferation and metastasis in vivo, thus explaining the negative role that this CAF subtype plays in patient outcomes. By contrast, FL CAFs do not promote these behaviors in cancer cells. Finally, we show that TCF21 expression in FH CAFs suppresses their protumorigenic phenotype.
While it has been known for some time that CAFs are heterogeneous (10, 18, 40) , only recently have distinct CAF subtypes begun to be identified and characterized. For example, a recent study showed that CAFs in close proximity to cancer cells in pancreatic cancer are αSMA+ myofibroblasts, whereas fibroblasts more distant from cancer cells lack elevated αSMA and instead secrete inflammatory cytokines (16) . A CAF subset defined by expression of CD10 and GPR77 varied in frequency in breast and lung cancers and was associated with resistance to chemotherapy and shorter patient survival (17) . Importantly, in both of these studies the identified subtypes were all FAP-positive, suggesting that they represent heterogeneity within the FH fraction. An additional study of breast cancer used multiple fibroblast markers to identify 4 CAF subsets, of which only one was FAP-positive ("S1") and 3 were FAP-negative ("S2-S4") (14) . Interestingly, the "S1" and "S4" subtypes were associated with aggressive HER2 and triple negative breast cancers, and triple negative breast cancer could be divided into two subgroups based on the presence of either S1 or S4 CAF subtypes. In a separate study the same group identified S1 and S4 CAFs in HGSOC (15) . They showed that "mesenchymal" samples are enriched for S1 CAFs, suggesting that S1 CAFs resemble our FH CAFs. However, the S4 CAFs quickly died and could not be maintained in culture, thus the authors were unable to carry out significant characterization of these cells. In addition, no analyses were done to evaluate the clinical significance of the CAF subtypes they identified. Thus our work represents a significant advance beyond these important early studies, through demonstration of the clinical significance of CAF heterogeneity in HGSOC, as well the extensive functional and molecular characterization of isolated CAF subtypes.
The seminal studies by Givel et al (15) and Costa et al (14) showed that FAP-positive CAFs have immunosuppressive functions in HGSOC and breast cancer. Other studies have also demonstrated an immune-suppressive function of FAP-expressing stromal cells (11) (12) (13) . We find a large cluster of pathways involved in immune regulation in FH CAFs ( Figure 3D , Table S4A ), which include many chemokines and cytokines involved in immune processes such as generation of myeloid-derived suppressor cells (e.g. CXCL12, IL11, VEGF), macrophage polarization (e.g. CXCL12, IL10, Chi3L1), differentiation of immune suppressive T regulatory cells (e.g. IL1B, IL10, IL11) and inhibition of CD8+ cytotoxic T cells (e.g. PDCD1LG2, LGALS1). Thus future work should include analysis of immune subtypes present in FH vs FL patients and understanding the cross-talk between subtypes of CAFs and immune cells in this cancer. By contrast, the FL CAFs have a distinct gene expression profile that lacks the secretory phenotype seen in FH cells.
Prominent networks include translation/protein localization, ion transport/cardiac muscle contraction, and lipid metabolism and steroid biosynthesis. The latter is in agreement with our finding that FL cells grew preferentially in pre-adipocyte media, which contains low serum plus supplements that include EGF and compounds that are pro-adipogenic such as dexamethasone, 3isobutyl-1-methylxanthine (IBMX) and ciglitazone, a PPAR agonist. However, the prominent muscle contraction network suggests that these cells may have a more primitive mesenchymal progenitor phenotype that has both myogenic and adipogenic potential. Comparison of the FL gene signature to published mesenchymal stem cell (MSC) signatures, however, suggests that these cells are not MSCs. Indeed, MSCs more closely resemble FH CAFs as they have elevated expression of FAP as well as multiple ECM proteins and ECM remodeling enzymes (41, 42) , thus further investigations, including functional assays, will be required to better elucidate the origin and/or identity of FL CAFs. For example, it will be of interest to compare the abilities of FH and FL CAFs to differentiate into various mesenchymal lineages and to determine if additional manipulations of the culture conditions can identify a condition that can maintain FL CAFs indefinitely in vitro.
Altogether, our functional assays suggest that the worse survival outcomes of patients with a FH gene signature and/or a predominance of FH CAFs within their stroma are mediated by CAFcancer cell interactions that promote cancer cell proliferation, invasion, and therapy resistance, as well as immune-suppression as shown by others (15) . There was some variability between individual FH CAF lines in their ability to influence these properties, and also variability in cell lines in their responses (e.g., the carboplatin response of OV90 cells was not affected by FH CAFs).
This suggests different mechanisms for each of the induced behaviors, as well as different responses between individual tumors. In spite of this variation, our results indicate that future studies focused on targeting FH CAFs in order to improve outcomes and/or responses to standard chemotherapy or immunotherapy are warranted.
The unique transcriptional programs of FH and FL CAFs prompted us to more closely examine differentially expressed transcription factors between the two CAF subtypes and TCF21 was the most highly differentially expressed transcription factor in FL cells. TCF21 is expressed in epicardial progenitor cells that give rise to coronary artery smooth muscle cells and cardiac fibroblasts (38) , the latter of which are a source of activated myofibroblasts in the infarcted heart (43) . TCF21 is also a marker for white adipose tissue and is abundantly expressed in visceral fatderived stem cells (44) . When we overexpressed TCF21 in FH CAFs, our results indicated that TCF21 on its own can significantly dampen the ability FH CAFs to promote gel contraction, invasion, chemo-resistance and in vivo tumor growth. However, additional transcription factors or co-regulators of TCF21 and/or epigenetic regulators of chromatin accessibility are likely required to completely reprogram FH CAFs to a state that lacks pro-tumorigenic properties. Future epigenomic profiling studies will be required to compare the epigenetic states of FH and FL CAFs and identify potential avenues to "reprogram" FH CAFs to a state that is not supportive of cancer cell invasion, chemoresistance or immune suppression.
Materials and Methods
Primary CAF Cultures
CAFs were derived from either bulk tumor cell suspensions or FACS purified cells (see 
Primary Tumor Dissociation
Bulk tumors were mechanically minced into a slurry with sterile scalpels and then enzymatically digested in Media 199 containing 300 U/ml Collagenase and 100 U/ml Hyaluronidase mixture (Stem Cell Technologies) and 125 U/ml DNAse-I (Cedarlane) for 1-2 hours at 37°C. Following digestion, samples were centrifuged at 350 x g for 5 minutes prior to treatment with 1-2ml of ACK lysing buffer (ThermoFisher Scientific) for 5 minutes on ice.
Following red cell lysis, cells were pelleted, resuspended and filtered through a 70 µm sterile nylon mesh and viable cells defined by trypan blue exclusion. Cells were cryopreserved in 90% FBS/10% dimethyl sulfoxide.
High-Throughput Flow Cytometry (HT-FC)
HT-FC was performed on cultured CAFs and primary HGSOC tumor cell suspensions as previously described (20) . Briefly, 363 commercially available antibodies to cell surface antigens 
Immunofluorescence -Cytospins
FACs-sorted cells were suspended in PBS+2% FBS at a concentration of 5x10 4 cells/ml and 200 µl of cell suspension were spun onto each glass slide using a cytocentrifuge at 800 rpm for 5 minutes. Slides were air-dried, fixed in 100% ice cold acetone and air dried again. Cells were permeabilized in Tris-buffered saline (TBS) containing 0.1% Tween for Cytokeratin and Vimentin, or 0.3% Triton X-100 for p53 (TBS-T) for 10 minutes, then incubated for 30 minutes in TBS-T/5% BSA/5% goat serum, followed by incubation with the following antibodies: rabbit anti-wide spectrum Cytokeratin (Abcam; 1:100), mouse-anti-human Vimentin (Abcam; 1:100), mouse-anti-human p53 (Santa Cruz; 1:100) overnight at 4°C. The following day, slides were washed 3 times in TBS and incubated with the appropriate secondary antibodies: goat-anti-rabbit-Alexa594 (Invitrogen; 1:1000) plus goat-anti-mouse-Alexa488 (Invitrogen; 1:400) for pan-CK and Vimentin; or goat-anti-mouse-Alexa594 (Invitrogen; 1:200) for p53. Secondaries were incubated for 1 hour at room temperature. Slides were then washed and incubated for 1 minute in TBS with 1 µg/ml Hoechst 333258, then coverslipped with Mowiol 4-88 (Sigma).
Immunofluorescence -FFPE Tissue Sections
Paraffin blocks of HGSOC tissues from 5 patients were obtained from the UHN Biospecimen Sciences Program (UHN, Toronto, ON) in accordance with regulations for excess tissue use stipulated by the UHN research ethics board. 4 µm sections were transferred onto positively-charged slides. Sections were deparaffinised using xylene and ethanol. For antigen retrieval, slides were incubated in 0.01 M citrate buffer (pH 6.0) with 0.05% Tween in a glass vessel submerged in boiling water for 20 minutes. Sections were then permeabilized in TBS-T (containing 0.1% Tween for Cytokeratin, CD49e and FAP, and 0.3% Triton X-100 for TCF21) for 10 minutes. Sections were incubated for 2 hours in TBS-T/0.5% BSA/5% goat serum, followed by incubation with rabbit anti-human TCF21 (Sigma, 1:100), mouse-anti-human-CD49e (BD Biosciences, 1:100), mouse-anti-human-FAP (R&D Systems, 1:50), and either mouse-anti-pan-Cytokeratin (Abcam, 1:100), or rabbit anti-wide spectrum Cytokeratin (1:100) overnight at 4°C.
The following day, slides were washed 3 times and incubated with goat-anti-rabbit-Alexa594 
TCGA Data Analysis
To identify genes specific to FH and FL CAFs, genes differentially expressed between FH and FL fractions at a FDR cut-off of 0.05 and with a logFC greater than 2 fold (logFC >2 for FH and <-2 for FL) were selected. These genes were then filtered to include only those that have a higher expression in CD49e+ cells compared to EpCAM+ CD133+ at a FDR cut-off of 0.05 in the Human Illumina HT-12 V4 array. This generated a list of 165 FH CAF-specific genes and 78 FLspecific genes.
HGSOC data were downloaded from the Genomic Data Commons (GDC) Data Portal (https://portal.gdc.cancer.gov/). HiSeq gene level counts (level2 RNA-Seq data) and
corresponding clinical data were downloaded for 374 samples included in this analysis.
Trimmed mean of M values (TMM) followed by count per million (CPM) and logarithm of base 2 transformation was used to normalize the data within the edgeR package. Data were selected to only contain the FH and FL gene list and a heatmap was created using R heatmap.2.
Color bars were added to the heatmap to identify patients based on molecular phenotype described by Verhaak et al (28) . These phenotypes include the categories 'mesenchymal', 'immune', 'proliferative', and 'differentiated' and they were extracted from Supplemental Table 1 of Verhaak et al (28) . Differential expression was calculated within edgeR for samples defined as 'mesenchymal' versus all the other samples and a list ranking genes from top up-regulated to down regulated was generated using the formula 'sign(logGC) * -log10(pvalue)'.
FH and FL color bar: TCGA patients were ranked using a score that counts how many genes from the FH gene list or FL gene list have a normalized value greater than the patient mean (i.e. a z-score). Patients were considered FH if they had positive scores for at least 75% of the gene list (corresponding to a sum of z-scores > gene list length/2). A less tringent threshold classified patients as FH or FL if they had positive scores in at least 50% of the gene list (corresponding to a sum of z-scores > 0). The FH and FL patient categories were added to the heatmap color bar and used for further analysis.
TCGA patients were then grouped into 'FH' and 'FL' and 'other' categories using either the 75% or the 50% thresholds and ESTIMATE and ABSOLUTE values, which are known to measure percentage of stromal cell and tumor purity content, respectively (29, 31) were determined using the respective R packages. Data were plotted on a whisker boxplot for each category. Clinical data including overall survival and progression free events were retrieved for TCGA patients falling into the FH and FL categories based on the more stringent 75% cut-off and Kaplan-Meier curves were generated and associated with a log rank test using GraphPad Prism software.
For GSEA testing of the short FH and FL lists in the 'mesenchymal' subtype, the mesenchymal rank list was tested against the short FH and FL gene lists using default parameters. Plates were left for 20 minutes at room temperature to solidify, then 120 µl IMDM + 10% FBS was added to the wells. A small pipet tip was gently run around the perimeter of each well prior to imaging on the Incucyte ZOOM every 6 hours for 3 days. The areas of the gels at different time points were quantified using ImageJ (Fiji) software. 
Gel Contraction
3D Spheroid Invasion Assays
In Vivo Assays
HGSOC OVCAR8 cells constitutively expressing firefly luciferase were mixed with FH, FL, 851FH-TCF21 or 851FH-GFP CAFs at a ratio of 5:1 (CAF: cancer cells). OVCAR8 cells alone were used as a control. Spheroids were formed as described above and suspended in a final volume of 100 µl IMDM media supplemented with 2% FBS. 100 µl of growth factor reduced Matrigel was added to the wells, mixed gently, then immediately loaded into blunt-end 16 gauge syringes (Stemcell Technologies, 28110). 6-8 week old female NSG mice were anaesthetized with isoflurane and an incision was made near the fourth mammary fat pad. Spheroids were then implanted into the fat pad directly and the incision was stapled. Mice were injected weekly with 30 mg/ml luciferin (Cedarlane) and imaged using a Xenogen IVIS Imaging System 100. Signal was quantified using IVIS Living Image software.
Lentiviral Constructs
Custom lentiviral vectors were designed and plasmids obtained using VectorBuilder (Cyagen Biosciences). A PGK promoter-driven TCF21-P2A-GFP lentiviral vector and control PGK-GFP and PGK-mCherry vectors were designed and purchased from Vectorbuilder (Cyagen Biosciences). For lentiviral infections cells were plated in 6-well plates at 1.0×10 5 cells per well and incubated with viral supernatants for 48 hours at 37°C. Infected cells were purified by FACS on the basis of GFP or mCherry expression and expanded for further use.
TCF21 Western Blot
851FH-GFP and 851FH-TCF21 CAFs were lysed in RIPA lysis buffer supplemented with EDTA-free protease inhibitor cocktail tablets (Roche) and normalized for total protein amount. 35 µg of protein from each sample were resolved in a 12% SDS-PAGE gel, and transferred onto Immobilon-P membranes (Millipore) using a semi-dry transfer method (Bio-Rad). Blots were probed overnight at 4°C using a mouse-anti-human ERK2 antibody (Santa Cruz; 1:1000) and a rabbit-anti-human TCF21 antibody (Sigma; 1:250), followed by a 45-minute incubation at room temperature with a goat anti-mouse IgG HRP-linked secondary antibody (Invitrogen, 1:1000), and goat-anti-rabbit IgG HRP-linked secondary antibody (Cell Signaling, 1:2500). Proteins were detected using enhanced chemiluminescence reagent (ThermoFisher) and autoradiograph exposure (Sigma-Aldrich).
Quantification and Statistical Analysis
Information about statistical details and analysis of microarray and RNAseq data is indicated in text, figure legends, or method details. Graphs and statistical values (p-values, correlation coefficients, hazard ratios) were generated using Graphpad Prism 6.03. Error bars indicate standard error of the mean (SEM) or standard deviation (SD) for a minimum of three independent experiments.
Data Availability
Microarray and RNA-seq data that support the findings of this study have been deposited at NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE126133.
Study Approval
Tumor samples were obtained from 69 patients with high grade serous ovarian cancer who underwent surgery at the University Health Network ( Table S1a) Table S1B . Recurrence Data for Patients in Figure 4E . Table S1B for recurrence data). (C) qRT-PCR for FH genes (FAP, SULF1) and FL genes (TCF21, DLK1) in passaged FL cells (red; passage # indicated below each bar). A cultured patient-derived CAF line was used as a control (black bar). Folddifferences in gene expression were determined using the -Ct method, using UBC as a housekeeping gene, with 3 technical replicates per sample assayed. (D) Representative images of collagen gels cultured for 36 hours with two FH derived CAF lines and two FL-derived CAF lines (left); quantification of gel contraction over time (right). Mean ± SEM, n=4. P-values for comparisons between FH and FL lines ranged from 0.02 to 0.002, two-way ANOVA. Scale bar = 500 µm. (E) Representative images of spheroids generated using GFP-expressing HGSOC cell lines OVCAR8, ES2 or OV90 combined with FH or FL fibroblasts (left). Circularity was quantified OVCAR8 and OV90 cells, and the number of cells outside the spheroid was quantified for ES2 cells (right). Data is normalized to spheroids containing no CAFs. Mean±SEM, n=5 to 10 spheroids per condition. P-values calculated using Student's t-test. Scale bar = 100 µm. # The difference between 438FL and 68425FH in OVCAR8 cells was not significant. (F) Growth curves of GFP-labelled cancer cells co-cultured with FH or FL CAFs after treatment with 10 µM carboplatin. Experiments were done in two separate batches ("Set 1" and "Set 2"). CAF line 851FH was used in both experiments. Data was normalized to the GFP+ area at Day 0. Mean±SEM, n=3. Asterisks reflect differences at the end of 10 days. **p<0.01, ****p<0.0001, Student's t-test. B A C Figure 6 . FH but not FL CAFs promote in vivo tumor growth and metastasis. (A) Spheroids of luciferase-expressing OVCAR8 cells alone or combined with FH or FL CAFs were generated as for invasion assays. After 72 hours of spheroid formation, individual spheroids were implanted into the mammary fat pads of NSG mice. Tumor growth was monitored over time using the Xenogen IVIS Imaging System 100. Representative images of a single mouse from each condition over time are shown. All mice were exposed for the same amount of time to allow visualisation of differences in tumor size over time. See also Figure S5B. (B) Quantification of luciferase signal, normalized to an unimplanted mouse over a period of 8 weeks. Mean±SEM, n=5 to 10 (animals in which tumors failed to grow were not included). **p<0.01, vs control group, linear regression. (C) Average tumor sizes in each group at 8 weeks and 11 weeks post-implantation. Numbers above the bars indicate the number of mice with metastases over the total number of tumor-bearing mice in each group. Mean±SEM, n=5 to 10. 
